Public summary of opinion on orphan designationN-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide for the treatment of Friedreich’s ataxia,

12 October 2010
EMA/COMP/455242/2010
Committee for Orphan Medicinal Products.

On 1 October 2010, orphan designation (EU/3/10/793) was granted by the European Commission to Repligen Europe Limited, Ireland, for N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide for the treatment of Friedreich’s ataxia.